RG
VRTX icon

Rathbones Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Rathbones Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$426K Sell
955
-289
-23% -$135K ﹤0.01% 470
2025
Q4 		$564K Hold
1,244
– – ﹤0.01% 437
2025
Q3 		$487K Sell
1,244
-7
-0.6% -$2.92K ﹤0.01% 445
2025
Q2 		$557K Hold
1,251
– – ﹤0.01% 419
2025
Q1 		$607K Sell
1,251
-203
-14% -$94.6K ﹤0.01% 391
2024
Q4 		$586K Hold
1,454
– – ﹤0.01% 397
2024
Q3 		$676K Buy
1,454
+355
+32% +$171K ﹤0.01% 373
2024
Q2 		$515K Sell
1,099
-570
-34% -$247K ﹤0.01% 411
2024
Q1 		$698K Buy
1,669
+179
+12% +$75.7K ﹤0.01% 368
2023
Q4 		$606K Buy
1,490
+227
+18% +$83.9K ﹤0.01% 370
2023
Q3 		$439K Buy
+1,263
New +$442K ﹤0.01% 417

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Rathbones Group's VRTX Position: Q1 2026 in Review

Rathbones Group reduced its Vertex Pharmaceuticals (VRTX) stake by 23% in Q1 2026, selling an estimated $135K and leaving 955 shares worth $426K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Rathbones Group first reported a position in VRTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $698K in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Rathbones Group held 955 shares of Vertex Pharmaceuticals worth $426K as of Q1 2026.
  • Rathbones Group sold 289 Vertex Pharmaceuticals shares in Q1 2026, an estimated $135K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Rathbones Group's portfolio in Q1 2026, its #470 holding.
  • Rathbones Group first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Rathbones Group's Vertex Pharmaceuticals position peaked at $698K in Q1 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.